Breaking News, Collaborations & Alliances

ProBioGen and Marea Therapeutics Accelerate MAR002 Antibody

Complete a sprint project to deliver clinical material for the investigational anti-growth hormone receptor (GHR) antibody.

Author Image

By: Charlie Sternberg

Associate Editor

ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly. The partnership encompassed cell line development, process development, formulation development, and GMP manufacturing services. The collaboration leveraged ProBioGen’s CHO.RiGHT cell line development platform, including its proprietary DirectedLuck transposas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters